Objective: Based on randomized controlled trials (RCTs), non-fatal myocardial infarction (MI) rates range between 9 and 15 events per 1000 person-years, ischemic stroke between 4 and 6 per 1000 person-years, CHD death rates between 5 and 7 events per 1000 person-years, and any major vascular event between 28 and 53 per 1000 person-years in patients with atherosclerotic cardiovascular disease (ASCVD). We reviewed global literature on the topic to determine whether the real-world burden of secondary major adverse cardiovascular events (MACEs) is higher among ASCVD patients. Methods: We searched PubMed and Embase using MeSH/keywords including cardiovascular disease, secondary prevention and observational studies. Studies published in the last 5 years, in English, with 50 subjects with elevated low-density lipoprotein cholesterol (LDL-C) or on statins, and reporting secondary MACEs were included. The Newcastle-Ottawa Scale (NOS) was used to assess the quality of each included study. Results: Of 4663 identified articles, 14 studies that reported MACE incidence rates per 1000 personyears were included in the review (NOS grades ranged from 8 to 9; 2 were prospective and 12 were retrospective studies). Reported incidence rates per 1000 person-years had a range (median) of 12.01-39.9 (26.8) for MI, 13.8-57.2 (41.5) for ischemic stroke, 1.0-94.5 (21.1) for CV-related mortality and 9.7-486 (52.6) for all-cause mortality. Rates were 25.8-211 (81.1) for composite of MACEs. Multiple event rates had a range (median) of 60-391 (183) events per 1000 person-years. Conclusions: Our review indicates that MACE rates observed in real-world studies are substantially higher than those reported in RCTs, suggesting that the secondary MACE burden and potential benefits of effective CVD management in ASCVD patients may be underestimated if real-world data are not taken into consideration.
Introduction
Cardiovascular diseases (CVDs) are the number one cause of death globally, responsible for at least one-third of all deaths in individuals over 35 [1] [2] [3] [4] [5] . CVDs, caused by disorders of the heart and blood vessels, include coronary heart disease (e.g. myocardial infarction [MI], angina), cerebrovascular disease (stroke) and peripheral arterial disease. In 2014, up to 11.5% of the adult population in the US was diagnosed with CVD 4,6 . The American Heart Association has projected that by 2035 up to 45% of the US population will have CVD 4 .
Age-adjusted death rates due to coronary heart disease and stroke have been falling since 1968, although this fall may be lessening 7 . Conversely, a progressive rise in the incidence and prevalence of atherosclerosis and coronary heart disease continues with increasing longevity in both men and women 8 . Atherosclerotic cardiovascular disease (ASCVD), a diffuse condition that involves the build-up of plaque in arterial walls, is directly associated with elevated levels of low-density lipoprotein cholesterol (LDL-C) 9, 10 . In 2012, about 73.5 million adults in the US had elevated LDL-C levels 11 .
Although the general improvement in CVD mortality rates has been documented, the real-world burden of secondary CVD events in patients with elevated LDL-C is unclear. It is especially important to examine real-world evidence (RWE) as clinical trials of other conditions typically report lower incident rates 12 . In order to understand the current burden of CVD worldwide in people with prior major adverse cardiovascular events (MACEs) and elevated LDL-C, we conducted a systematic literature review of real-world global literature on the topic.
Methods

Data sources and search strategy
Literature searches were conducted in PubMed and Embase (in February and March 2017, respectively) using Medical Subject Headings (MeSH) terms and other appropriate keywords ( Table 1 ). The literature review adhered to established guidance as defined by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement 13 . The search strategy was limited to the studies published in the last 5 years and limited to the English language. To ensure that the search strategy captured relevant literature, we confirmed that five relevant articles were identified.
Eligibility criteria
The review was conducted using a pre-specified protocol. Eligibility criteria were defined in terms of the population, interventions, comparisons, outcomes and study design (PICOS framework) 14 . The population and interventions of interest included patients with a history of ASCVD, elevated LDL-C, hypercholesterolemia or hyperlipidemia, or receiving lipid lowering treatment (e.g. statins). Prior MACEs were defined as: acute coronary syndrome (ACS), MI, non-ST-segment elevation myocardial infarction (NSTEMI), ST-segment elevation myocardial infarction (STEMI), ischemic stroke, sudden (cardiac) death, arrhythmias, unstable angina, ischemic (or dilated) cardiomyopathy, heart failure, and treatment interventions (coronary artery revascularization, coronary artery stenting, cerebral artery revascularization, carotid artery revascularization, coronary artery bypass grafting [CABG] , and percutaneous coronary intervention [PCI] ). Acceptable study designs included retrospective or prospective observational studies. Randomized controlled trials (RCTs) were excluded because a recently published comprehensive systematic review and meta-analysis of RCTs already reported MACE rates 15 .
To compare our RWE findings to RCT results, we examined this meta-analysis study in our review.
Study selection
Researchers experienced in literature reviews screened articles in three phases: an initial title/abstract screen and two rounds of full-text screens. Further study inclusion criteria required eligible studies to report outcomes of interest (see Outcome measures below) in 50 human subjects with elevated LDL-C, hypercholesterolemia, hyperlipidemia, or therapy with lipid/cholesterol lowering treatments and prior MACEs. The review was conducted using DistillerSR, a systematic review program (Evidence Partners, Ottawa, Canada).
Outcome measures
The outcomes of interest included quantitative rates of the following: angina, MACEs, coronary heart disease, heart failure, ischemic stroke, mortality (except mortality reported less than 3 months post-operation/hospitalization), MI and stroke. Other outcomes of interest included ACS (e.g. unstable angina, NSTEMI, STEMI), carotid artery revascularization, coronary artery revascularization (e.g. CABG, PCI), peripheral arterial disease, sudden cardiac death and transient ischemic attack (TIA).
Quality assurance
To ensure consistency during screening and abstraction across the multiple reviewers, each reviewer was trained prior ) OR (ischemic stroke))))) OR ((((percutaneous coronary) OR (coronary artery bypass) OR (revascularization) OR (revascularize) OR (revascularized) OR (angioplasty) OR (stent) OR (CABG)))))) AND ((((subsequent) OR (prior) OR (recurrent) OR (secondary prevention) OR (first) OR (second) OR (following) OR (preceding) OR (additional) OR (next) OR (after) OR (serial) OR (successive) OR (previous) OR (earlier) OR (consecutive))))) AND ((((low density lipoprotein) OR (LDL) OR (hyperlipidemia) OR (lipid lowering) OR (lipid modifying) OR (statin))))) AND ((((clinical study) OR (retrospective study) OR (cohort study) OR (cohort analysis) OR (longitudinal study) OR (observational study) OR (case control study) OR (cross sectional study) OR (registry) OR ("real world") OR (claim) OR (claims) OR (cost) OR (Clinical Trial, Phase IV)))) Filters: published in the last 5 years; English (treatments OR outcomes) AND secondary events AND patient population AND study types
Search (((((((((myocardial infarction) OR (cardiovascular death) OR (sudden death) OR (acute coronary syndrome) OR (cardiovascular events) OR (cardiovascular event) OR (ischemic stroke))))) OR ((((percutaneous coronary) OR (coronary artery bypass) OR (revascularization) OR (revascularize) OR (revascularized) OR (angioplasty) OR (stent) OR (CABG)))))) AND ((((subsequent) OR (prior) OR (recurrent) OR (secondary prevention) OR (first) OR (second) OR (following) OR (preceding) OR (additional) OR (next) OR (after) OR (serial) OR (successive) OR (previous) OR (earlier) OR (consecutive))))) AND ((((low density lipoprotein) OR (LDL) OR (hyperlipidemia) OR (lipid lowering) OR (lipid modifying) OR (statin))))) AND ((((clinical study) OR (retrospective study) OR (cohort study) OR (cohort analysis) OR (longitudinal study) OR (observational study) OR (case control study) OR (cross sectional study) OR (registry) OR ("real world") OR (claim) OR (claims) OR (cost) OR (Clinical Trial, Phase IV)))) study types
Search (((clinical study) OR (retrospective study) OR (cohort study) OR (cohort analysis) OR (longitudinal study) OR (observational study) OR (case control study) OR (cross sectional study) OR (registry) OR ("real world") OR (claim) OR (claims) OR (cost) OR (Clinical Trial, Phase IV))) patient population
Search (((low density lipoprotein) OR (LDL) OR (hyperlipidemia) OR (lipid lowering) OR (lipid modifying) OR (statin))) secondary events
Search (((subsequent) OR (prior) OR (recurrent) OR (secondary prevention) OR (first) OR (second) OR (following) OR (preceding) OR (additional) OR (next) OR (after) OR (serial) OR (successive) OR (previous) OR (earlier) OR (consecutive))) treatments
Search (((percutaneous coronary) OR (coronary artery bypass) OR (revascularization) OR (revascularize) OR (revascularized) OR (angioplasty) OR (stent) OR (CABG))) outcomes
Search (((myocardial infarction) OR (cardiovascular death) OR (sudden death) OR (acute coronary syndrome) OR (cardiovascular events) OR (cardiovascular event) OR (ischemic stroke))) a PubMed search string was adapted and reproduced in Embase.
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to beginning the literature review. During this training, each reviewer screened the same 30 title/abstracts during the title/abstract screen phase and the same 15 full-text articles during the full-text screen phase. The individual screening decisions were compared against a gold standard, which was developed by a senior researcher with expertise in systematic literature reviews. Reviewers had to achieve 70% agreement with the gold standard. Disagreements were reviewed and reviewers who did not achieve 70% agreement with the gold standard were trained further by thoroughly discussing each screening item, response and test study.
Risk of bias assessment
A single reviewer used the Newcastle-Ottawa Scale (NOS) to assess the quality of included studies, with possible grades ranging from zero (lowest quality) to nine (highest quality) 16, 17 . The risk of bias ratings for each study are reported in the supplementary material (Supplemental Appendix, Table 5 ).
Results
Search and screening overview
PubMed and Embase searches yielded 4663 articles following de-duplication ( Figure 1 ). In the first screening phase, 3057 of 4663 records were excluded. In phase two, 1606 full-length articles were reviewed, of which 1138 were excluded (e.g. 557 due to inappropriate patient population). In the final screening phase, 383 of 468 articles (e.g. 184 did not discuss outcomes of interest) were excluded. Eighty-five observational studies were abstracted in this review, of which 14 reported outcomes of interest as event rate standardized per patient-years (e.g. per 100, 1000, or 100,000) that allowed for comparison of results across the studies. Although the rest of the studies were relevant to this topic, the outcomes of interest were presented in highly variable formats, such as composite events and a variety of individual rates of MACEs over different follow-up periods, limiting the ability to synthesize results. Thus, these 14 studies are the focus of the current review.
Overview of included studies
Of the 14 included studies, 1 was conducted in Denmark, 1 in Israel, 1 in Spain, 3 in Taiwan, 1 in Thailand, 4 in the UK, and 3 in the US ( Table 2) . Two of the studies were prospective and 12 were retrospective, with sample sizes ranging from 601 to 273,308 per study. Thirteen studies had an NOS grade of 9 and one a grade of 8, indicating that the evidence was of high quality. Per-patient-year results reported by the 14 studies were standardized to per 1000 patient-years for clearer discussion in this review ( Table 3 ). Studies that reported MI, stroke, death and composite rates are discussed below. Finally, we summarized RCT results based on the Cholesterol Treatment Trialists' Collaboration (CTTC) metaanalysis 15 . A comparison of the RWE and RCT results can be found in Table 4 and Figure 2 .
Myocardial infarction rate
Four studies reported rates of MI incidence, which ranged from 12.01 to 39.9 (median: 26.8) per 1000 personyears 22, 23, 27, 28 . All investigated patients on lipid-lowering therapy.
Two large US studies included patients with ASCVD history. Huang et al. 22 analyzed the HealthCore Integrated Research Database from 2006 to 2014. Study patients had 1 ASCVD condition (ACS, coronary heart disease, stroke or 27, 28 . In one study, among patients with diabetes, the statin-exposed secondary prevention (SP) cohort (n ¼ 514) had a nonfatal MI incidence rate of 12.01 per 1000 person-years (95% CI: 8.34-17.28) 27 . In the study among patients with chronic kidney disease (CKD), the nonfatal MI incidence rate was 26.8 per 1000 person-years (95% CI: 20.6-34.9) among the statin-exposed secondary prevention cohort 28 .
Ischemic stroke/transient ischemic attack rates
Of the six studies that reported incidence rates of stroke, four specifically reported rates of ischemic or TIA stroke 18, 19, 22, 23 . All studies included patients on lipid-lowering therapy, while one additionally included patients with elevated LDL-C. Reported incidence of ischemic stroke ranged from 13.8 to 57.2 (median: 41.5) per 1000 personyears 18, 19, 22, 23 , while TIA incidence rates ranged from 7.2 to 13.2 per 1000 person-years 18, 22 .
Huang et al. 22 reported ischemic stroke rates of 16.1 in the high-intensity statin patients and 13.8 in the low-/moderate-intensity statin patients and TIA rates of 12.1 and 10.1 in the high-intensity and low-/moderate-intensity statin patients, respectively. In ASCVD patients with lipid-lowering therapy, Jena et al. 23 reported rates of ischemic stroke of 20.69 and 22.47 in patients with LDL-C 70 mg/dL and LDL-C 100 mg/dL, respectively. In a large Taiwanese study using the National Health Insurance Research Database (NHIRD), Chen et al. 18 examined 7243 adult patients with a first TIA or stroke in 2001 and 1 statin prescription. Incidence rate for ischemic stroke for in-hospital (initiated during index hospitalization, n ¼ 2019), "intermediate" (initiated within 1 year of discharge, n ¼ 2266), and "late" (initiated 1 year or later after discharge, n ¼ 2958) statin use groups were 39.7, 43.3, and 55.9, respectively. TIA rates among in-hospital, intermediate, and late statin use groups were 7.2, 11.5, and 13.2, respectively. Also using the NHIRD, Chen et al. 19 included patients with ischemic stroke or TIA between 2002 and 2005 who initiated statin therapy during hospitalization or within 3 months of discharge. Ischemic stroke rates among good, Rates per 1000 person-years statin-exposed SP cohort:
Non-fatal MI: 12.01 Rates per 1000 person-years statin-exposed SP cohort:
Non-fatal stroke: 12.05
Rates per 1000 person-years statin-exposed SP cohort:
CV death: 35.28 All-cause mortality: 51.16 n/a
Rates per 1000 person-years statinexposed SP cohort:
APTC end point: 44.63
Sheng et al. 2012 28 Rates per 1000 person-years, statin-exposed SP cohort:
Non-fatal MI: 26.8 Rates per 1000 person-years, statin-exposed SP cohort:
Non-fatal stroke: 15.5
Rates per 1000 person-years, statin-exposed SP cohort: intermittent and poor statin adherence groups were 47.0, 53.6 and 57.2, respectively 19 . The remainder of included studies reported incidence rates of unspecified stroke or definitions of stroke that included hemorrhagic stroke. The two Sheng et al. studies reported an incidence rate per 1000 person-years of nonfatal ischemic or hemorrhagic stroke of 12.05 (95% CI: 8.42-17.23) in diabetic statin-exposed patients 27 , and an incidence rate of 15.5 (95% CI: 11.0-21.9) in statin-exposed secondary prevention CKD patients 28 . In Thai patients with angina pectoris or MI discharges, Chinwong et al. 20 reported incidence rates for unspecified nonfatal stroke of 0, 4 and 0 per 1000 person-years in those with LDL-C <70 mg/dL, LDL-C 70-99 mg/dL and LDL-C 100 mg/dL, respectively. In currently statin-treated ischemic stroke patients in Denmark, Ostergaard et al. 26 
Mortality
Among the nine included studies reporting mortality rates, all evaluated patients on lipid-lowering therapy [20] [21] [22] [23] [26] [27] [28] [29] [30] . Incidence of CV-related mortality was reported in four studies, ranging from 1.0 to 94.5 (median: 21.1) per 1000 personyears 22, 23, 27, 28 . Incidence of all-cause mortality was reported in eight studies, ranging from 9.7 to 486 (median: 52.6) per 1000 person-years [19] [20] [21] [22] [26] [27] [28] [29] [30] .
Three studies included ASCVD patients. Danese et al. 21 examined UK patients treated with lipid-modifying therapy prior to their first MACE; cohorts were stratified by Charlson Comorbidity Score (0, 1 or 2þ). Reported death rates per 1000 person-years 6 months post MACE were 285 for the entire cohort, and 135, 227 and 420 by 0, 1 and 2þ scores, respectively. In the subsequent 30 months period, rates were 54 for the entire cohort, and 24 for score 0, 48 for score 1 and 84 for score 2þ. In patients with a subsequent event, death rates in a 6 month period were 365 for the entire cohort, and 87, 243 and 486 for 0, 1 and 2þ score subgroups, respectively. In the subsequent period, death rate was 62 per 1000 person-years for the entire cohort, with 14, 33 and 92 deaths per 1000 person-years for scores 0, 1 and 2þ, respectively. In Huang et al. 22 , all-cause mortality incidence rates per 1000 person-years in ASCVD patients on high-intensity statins or low-/moderate-intensity statins were 11.2 and 9.7, respectively, while CV-related mortality was 1.5 in the high-intensity statin group and 1.0 in the low-/moderate-intensity statin group. In another US study, patients with ASCVD treated with lipid-lowering therapy and LDL-C 70 mg/dL and 100 mg/dL had CVD mortality rates of 20.03 and 22.12 per 1000 person-years, respectively 23 .
In Sheng et al. 27 , statin-exposed patients with history of CVD and diabetes had a CV death incidence rate per 1000 29 , all-cause mortality rates per 1000 person-years in stroke patients with elevated LDL-C were 36.25 and 26.09 in the no statins and statins groups, respectively. Among ischemic stroke patients stratified by antiplatelet and statin use in Ostergaard et al. 26 , all-cause death rates per 1000 personyears were 38.2 (current antiplatelet), 36.9 (recent antiplatelet) and 50.7 (non-use antiplatelet).
Composite major adverse cardiovascular event rate
Eleven studies reported composite MACE rates, although definitions of the composite varied between studies 18-22,24,27-31 .
Of these, nine studies reported composite event rates, which ranged from 25.8 to 211 (median: 81.1) events per 1000 person-years [18] [19] [20] 22, 24, [27] [28] [29] 31 Four studies included patients with ASCVD. In the first event cohort in the acute 6 month period, Danese et al. 21 reported multiple MACE rates of 234, 234 and 288 per 1000 person-years for Charlson Comorbidity Scores 0, 1 and 2þ, respectively. In the subsequent 30 months, the multiple rates per 1000 person-years were 60 for score 0, 95 for score 1 and 122 for score 2þ. In the second event cohort, subsequent MACE rates per 1000 person-years in the acute period were 255, 380 and 391 for 0, 1 and 2þ score groups. For the long-term period, patients with score 0 had 111, score 1 had 126, and score 2þ had 196 multiple MACEs per 1000 personyears. Toth et al. 31 assessed UK data from CPRD, HES and the Office for National Statistics from 2004 to 2011. High-intensity statin treated patients with LDL-C 70 mg/dL or other dyslipidemias were categorized into high-risk ASCVD, incident ACS, incident ischemic stroke, and incident heart failure cohorts. The composite MACE rates per 1000 patient-years were 75 in the high-risk ASCVD cohort, 211 in the incident ACS cohort, 119 in the ischemic stroke and 163 in the heart failure cohorts; multiple event rates were 123, 257, 133 and 233, respectively. Excluding revascularization, the composite MACE rates were 64 in high-risk ASCVD, 148 in ACS, 112 in ischemic stroke and 131 in heart failure cohorts, while multiple event rates were 100, 183, 121 and 191, respectively. Leibowitz et al. 24 reported that the first occurrence of MACE (MI, unstable angina, stroke, PCI, CABG or all-cause mortality) per 1000 person-years was 78.1, 71.0, and 81.3 in patients with LDL-C 70 mg/dL, LDL-C 70.1-100.0 mg/dL, and LDL-C 100.1-130.0 mg/dL, respectively, among Israeli patients with prior MACEs and statin therapy. In Huang et al. 22 , composite rates (of ACS, stroke, coronary revascularization and CVrelated mortality) in ASCVD patients on high-intensity statins or low-/moderate-intensity statins were 103.1 and 87.0 per 1000 person-years, respectively.
Sheng et al. 27 reported recurrent Antiplatelet Trialist's Collaboration (APTC) events, including nonfatal MI, nonfatal 23, 25 Any coronary revascularization (CABG, PTCA, unspecified): 12-32 (26) stroke or death from vascular causes in statin-exposed patients with CVD and diabetes: 44.63 per 1000 person-years (95% CI: 36.65-54. 35 ). The APTC event rate in a statinexposed secondary prevention CKD population was 114.2 (95% CI: 99.7-130.8) 28 . Chinwong et al. 20 reported composite event rates (nonfatal ACS, stroke and all-cause death) which were 43, 66 and 88 per 1000 person-years in patients that achieved LDL-C <70 mg/dL, LDL-C 70-99 mg/dL, and LDL-C 100 mg/dL, respectively.
In a multicenter US study of over 5000 patients initiated on statins post-MI, the multiple event rate per 1000 personyears of CV hospitalization was 168.4 30 .
Three studies evaluated stroke patients. Chen et al. 18 reported rate per 1000 person-years of a composite endpoint of recurrent ischemic stroke, hemorrhagic stroke, acute coronary event and all-cause mortality. Rates in the in-hospital, intermediate and late statin use groups were 64.6, 68.1 and 85.9, respectively. In Chen et al. 19 , the composite rates (recurrent ischemic stroke, hemorrhagic stroke or acute coronary event) were 71.6, 80.9 and 87.3 per 1000 person-years in the good, intermittent and poor statin adherence groups, respectively. Sicras-Mainar et al. 29 reported rates of MACEs (ischemic heart disease, acute MI, fatal or non-fatal ischemic or hemorrhagic stroke) of 25.76 per 1000 person-years in statin-treated patients.
Randomized controlled trial results review
The CTTC conducted an extensive literature review and meta-analysis of 26 randomized clinical trials to assess the safety and efficacy of lowering of LDL-C with statin therapy 15 . Findings from these analyses indicate that further reductions in LDL-C safely lead to further reductions in the incidence of MACEs, including heart attack, revascularization and ischemic stroke 15 . Based on the point estimates among statin treated comparator cohorts from the 26 trials reported by the CTTC, the occurrence of a non-fatal MI per annum ranged from 0.9% to 1.5% (9-15 events per 1000 person-years), CHD death per annum ranged from 0.5% to 0.7% (5-7 events per 1000 person-years), any coronary revascularization (CABG, PTCA, unspecified) from 1.2% to 3.2% (12-32 events per 1000 person-years), any ischemic stroke from 0.4% to 0.6% (4-6 per 1000 person-years) and any major vascular event from 2.8% to 5.3% (28-53 per 1000 person-years) in statin users 15 . All-cause mortality was reported as 21 events per 1000 person-years. Table 4 and Figure 2 summarize MACE rates based on RWE and RCTs.
Discussion
Our comprehensive literature review summarizes the global real-world CVD burden in patients with prior MACEs and elevated LDL-C. We found that the MACE rates in RCTs were typically lower than the rates we identified in real-world studies. We compared the MACE rates observed in real-world studies with those reported in a recent comprehensive meta-analysis of 26 clinical trials 15 . According to the CTTC, non-fatal MI rates range from 9 to 15 events per 1000 person-years, while we found that MI rates range from 12.01 to 39.9 per 1000 person-years based on RWE. Further, RCT findings show ischemic stroke rates range from 4 to 6 per 1000 person-years versus from 13.8 to 57.2 per 1000 person-years in RWE studies. Similarly, CVD-related death rates were generally lower in RCTs than in real-world studies, with MACE rates ranging from 5 to 7 and 1.0 to 94.5 per 1000 personyears, respectively. Based on RCT data all-cause mortality is 21 events per 1000 person-years, while RWE indicates rates range from 9.7 to 486 in patients of interest. RCTs also report lower rates for coronary revascularization versus RWE, particularly for unspecified revascularization: 5-6 events versus 26.9-38.8 per 1000 person-years, respectively. Composite event rates are also higher in RWE studies versus RCTs: ranging from 25.8 to 211 versus 28 to 53 per 1000 person-years. Moreover, real-world data indicates multiple event rates ranging from 60 to 391 events per 1000 person-years. These findings indicate that the burden of secondary MACEs in clinical practice may be considerably higher than reported in clinical trials.
The importance of considering RWE has been discussed in prior studies 12, [32] [33] [34] . Although RCTs are considered the "gold standard" for establishing the efficacy of specific interventions, this methodological approach is probably not sufficient for describing the epidemiology and real-world disease burden in the general population. This is demonstrated by the stringent patient selection criteria (e.g. exclusion of high risk patients) and highly controlled clinical settings typically employed by RCTs, leading to limited generalizability of disease burden to the general population and routine clinical practices 12, [32] [33] [34] . Elliot et al. 12 found that rates of hypoglycemia were consistently higher in real-world studies compared to RCTs in patients with type 1 or type 2 diabetes. Toth et al. 34 found that cost-effectiveness analyses based on real-world rather than RCT data are more likely to conclude that a treatment is cost-effective, because RCTs are more likely to underestimate the true benefit of lipid-lowering therapies. Because of this, several national and international clinical and research organizations endorse the use of RWE in the evaluation of new technologies 34 . Together with prior research and evidence generated in this study, this data underscores the importance of conducting and considering observational population studies in CVD to produce generalizable disease burden estimates in a real-world setting.
Differences in results observed in RCTs versus observational studies are primarily associated with differences in the study populations, settings and outcomes 34, 35 . RCTs typically examine highly selected patient populations in tightly controlled and monitored settings and often focus on time-tofirst-event outcomes, while observational studies include patients that may be excluded from RCTs and focus on realworld conditions with greater variation in practice and patient settings and examine all relevant events 34, 35 . Specifically, prior research has examined potential key drivers of the differences in MACE results generated by RCTs and RWE. The differences primarily stem from the variations in definitions of CVD risk or CVD events, and dissimilarities in the composition of the study patient samples 34 .
The definitions of composite, multiple event and mortality rates in particular vary across studies. For example, RCTs typically report incident event rates, while RWE studies commonly report multiple event rates 21, 30, 31 . It is important to be aware whether an incident or a multiple event rate is reported since not only are the fundamental interpretations of the two values are different but the absolute values resulting from these measures are also dramatically different. Further, individual events included in the composite tend to differ across studies. For example, the Antiplatelet Trialist's Collaboration event endpoint in Sheng et al. 27, 28 included non-fatal MI, non-fatal stroke and CV death, while the composite in Chen et al. 18 included ischemic stroke, TIA, hemorrhagic stroke and acute coronary event. Additionally, MACE rate estimates may vary due to database limitations. Administrative health insurance claims databases, often examined in RWE studies, lack mortality data and prevent direct linking to official death records due to de-identification of the analytic datasets 22 . Even if linkage is possible, assessment of mortality is poor since patients can disappear from a claims database due to disenrollment from a health plan or claims may be missing due to coding errors. These may be the reasons for the substantially low mortality rates observed by Huang et al. 22 , particularly since the CV-related mortality algorithm included a requirement of 1 inpatient stay or emergency department visit with a MACE as a primary diagnosis within 30 days of death 22 . Yet, a lack of a relevant claim in the database does not guarantee absence of an event of interest; thus, the mortality rates in Huang et al. 22 were likely underestimated.
The growing burden of CVD and the changing landscape of CVD management have also been well documented worldwide 4, 8, [36] [37] [38] [39] [40] [41] [42] [43] [44] . Most recent projections indicate that up to 45% of the US population will have CVD by 2035, with costs skyrocketing from $555 billion in 2016 to $1.1 trillion by 2035 4 . Similarly, increased CVD burden projections have been shown for the UK and China 38, 39 . Several recent large scale cross-sectional surveys in European countries revealed that, despite lipid-lowering drugs, 30%-80% of the surveyed patients with coronary heart disease remained above the recommended lipid targets, depending on the LDL cholesterol target 43, 44 . Fleg et al. 8 explains that there is a progressive rise in the incidence and prevalence of CHD with increasing longevity in both men and women. The aging and growth of the world's population have led to rising numbers of CVD deaths and, moreover, low-and middle-income countries are confronted by an increasing number of people experiencing CVD at younger ages 36, 42 . Our findings further underscore the global burden of CVD and the importance of generating RWE to better understand the true burden of this disease.
Limitations
The strength of this review lies in its comprehensive search, review and synthesis of global literature on secondary MACE rates in patients with ASCVD. NOS grades for the 14 studies included in the review were all 9, with the exception of one which had a grade of 8. This study also has limitations. By design this review only examined observational studies.
The studies included in this review varied in design, patient population, treatments and definitions of outcomes, and the data were reported in several ways across the reviewed studies. Thus, the heterogeneity of the data made it difficult to compare directly between studies and prevented us from conducting a meta-analysis. In addition, although this was a rigorous systematic literature review on multiple broad research topics using PubMed and Embase, a search of different literature databases and implementation of a different variety of search terms and search strings may have yielded somewhat different results. We present all-cause mortality results in this review; however, these findings should be considered with caution since it has been previously argued that interventions should not be withheld until they have been proven to reduce all-cause mortality 45 . It should also be noted that health insurance claims databases, examined by several of the studies in this review, are designed for administrative purposes, not for research; as with any coded data, under-or over-coding may have occurred. Finally, despite the observational nature of the studies in this review, some MACE outcomes of interest, such as CV-related mortality, may have been underestimated for various reasons, e.g. due to limited study follow-up periods, event identification algorithms, coding errors or limited availability of relevant information in the databases.
Conclusions
Our review indicates that MACE rates observed in real-world settings are substantially higher than those rates reported in RCTs. These results suggest that the true secondary MACE burden and potential benefits of effective CVD management among ASCVD patients may be underestimated if real-world data is not considered.
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